The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models.
暂无分享,去创建一个
Wei Zhang | Xiaoling Fang | Yanzuo Chen | Wei Zhang | Yuan-Ping Shi | Xiao-ling Fang | X. Sha | Junguo Hao | Yanzuo Chen | Xianyi Sha | Junguo Hao | Yuan Shi
[1] Wei Liang,et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. , 2007, Journal of the National Cancer Institute.
[2] Chiraphon Chaibundit,et al. Micellization and gelation of mixed copolymers P123 and F127 in aqueous solution. , 2007, Langmuir : the ACS journal of surfaces and colloids.
[3] R. Emanuele,et al. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. , 2002, Journal of pharmaceutical sciences.
[4] Tal Dvir,et al. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. , 2011, Biomaterials.
[5] C. Gau,et al. Interfacial properties of Pluronics and the interactions between Pluronics and cholesterol/DPPC mixed monolayers. , 2008, Journal of colloid and interface science.
[6] Gert Storm,et al. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.
[7] Hong Yuan,et al. Core-modified chitosan-based polymeric micelles for controlled release of doxorubicin. , 2008, International journal of pharmaceutics.
[8] T. Johnston,et al. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. , 1992, Journal of pharmaceutical sciences.
[9] Alexander V Kabanov,et al. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[10] Hong Yuan,et al. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. , 2009, Biomaterials.
[11] Li-Fang Wang,et al. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[12] S. Gaisford,et al. Diode-array UV spectrometric evidence for cooperative interactions in binary mixtures of Pluronics F77, F87, and F127 , 1997 .
[13] Xiaoling Fang,et al. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. , 2009, International journal of pharmaceutics.
[14] Yongzhong Wang,et al. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles , 2008, Archives of pharmacal research.
[15] Hong Yuan,et al. Coadministration of glycolipid-like micelles loading cytotoxic drug with different action site for efficient cancer chemotherapy , 2009, Nanotechnology.
[16] G. Badun,et al. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers , 1999, FEBS letters.
[17] Leaf Huang,et al. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] Véronique Préat,et al. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[19] S. Alberts,et al. Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases. , 2006, Clinical colorectal cancer.
[20] Kan Wang,et al. Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy. , 2010, Biomaterials.
[21] M. Ranson,et al. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Jordan,et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] Xiao-ling Fang,et al. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123 , 2006, Acta Pharmacologica Sinica.
[24] Yolonda L Colson,et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. , 2009, Journal of the American Chemical Society.
[25] A. Kabanov,et al. Distribution kinetics of a micelle-forming block copolymer Pluronic P85. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[26] Jinming Gao,et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. , 2010, Cancer research.
[27] Shiladitya Sengupta,et al. Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma , 2010, Nanotechnology.
[28] J. Xie,et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.
[29] W. Pitt,et al. Drug delivery in polymeric micelles: from in vitro to in vivo. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[30] Z. Hua,et al. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] Xiaoling Fang,et al. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32] E. Frenkel,et al. Nanoparticles for drug delivery in cancer treatment. , 2008, Urologic oncology.